Lung cancer treatment from Heat Bio continues to show promise in clinical trial
RESEARCH TRIANGLE PARK – Durham-based Heat Biologics just got a little hotter. The clinical-stage biopharmaceutical company reported positive interim results from a phase 2 clinical trial of its therapy to treat advanced non-small cell lung cancer (NSCLC). Heat said the drug, HS-110 – used in combination with Bristol-Myers Squibb’s immune checkpoint inhibitor, OPDIVO – provided “substantial survival benefit” in a group of previously treated, checkpoint inhibitor naïve patients with advanced NSCLC. HS-110 is a cell-based therapy that activates patients’ immune systems to fight...
Source: wraltechwire.com
